Veterinary Drug Applications
This article was originally published in SRA
Interim policy for outstanding responses to additional data requests
You may also be interested in...
A Medicines for Europe report on policies affecting the off-patent industry across 22 European countries aims to demonstrate the urgent need for pricing and reimbursement and procurement reforms.
After a difficult spell for the Belgian biotech, positive interim data from two key studies looking at testicular toxicity concerns over filgotinib suggest a pathway for potential future US approval of the Gilead-partnered JAK inhibitor for IBD.
Stada has appointed a new specialty head who will have global responsibility for the firm’s biosimilars business. Meanwhile, Hyloris has named a new business development chief and a generics industry veteran has joined Slayback’s board.